<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04676334</url>
  </required_header>
  <id_info>
    <org_study_id>CO-338-111</org_study_id>
    <nct_id>NCT04676334</nct_id>
  </id_info>
  <brief_title>CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib</brief_title>
  <acronym>CATCH-R</acronym>
  <official_title>CATCH-R: A Rollover Study to Provide Continued Access to Clinical Therapy With Rucaparib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clovis Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clovis Oncology, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol is designed to provide patients currently benefiting from rucaparib treatment&#xD;
      in a Clovis-sponsored clinical study with continued access to treatment for as long as they&#xD;
      continue to benefit. Patients in long-term follow-up (LTFU) in a parent study may also enroll&#xD;
      in this study for continued data collection, as applicable based on parent study objectives.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients enrolled in this study are required to have completed an End-of-Treatment (EOT)&#xD;
      Visit with associated assessments as specified in the Clovis-sponsored parent study. Patients&#xD;
      who are no longer receiving treatment and are in LTFU in the parent study may enroll into the&#xD;
      LTFU portion of this study, as applicable based on parent study objectives, without repeating&#xD;
      the EOT visit.&#xD;
&#xD;
      The starting dose of rucaparib administered at initiation of this study will be the same as&#xD;
      the last dose received in the parent study, or as deemed appropriate by the investigator and&#xD;
      based on available dose strength tablets. The first treatment in the rollover study will&#xD;
      begin at the next scheduled treatment visit following the EOT Visit in the parent study.&#xD;
&#xD;
      Patients enrolled to receive continued rucaparib may be treated until disease progression, as&#xD;
      assessed by the investigator, unacceptable toxicity, withdrawal of consent, death, loss to&#xD;
      follow-up, or study closure by the sponsor. If a patient demonstrates disease progression per&#xD;
      investigator assessment while receiving treatment with rucaparib but continues to derive&#xD;
      clinical benefit, then continuation of treatment beyond progression is permitted based on&#xD;
      investigator decision and patient consent. If a patient continues treatment post-progression,&#xD;
      all study assessments should be continued per institutional standard of care. The patient&#xD;
      should be discontinued from treatment once it is clear that no further clinical benefit can&#xD;
      be achieved.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">March 22, 2021</start_date>
  <completion_date type="Anticipated">January 2, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety follow-up</measure>
    <time_frame>Baseline up to approximately 3 years</time_frame>
    <description>Serious adverse events and adverse events of special interest reported until 30 days after the last dose of study drug.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Metastatic Castration-Resistant Prostate Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Epithelial Ovarian Cancer</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Peritoneal Cancer</condition>
  <condition>Other Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Rucaparib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rucaparib administered at dose and schedule last taken in parent study, or per investigator decision</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rucaparib</intervention_name>
    <description>Rucaparib will be administered daily.</description>
    <arm_group_label>Rucaparib</arm_group_label>
    <other_name>CO-338</other_name>
    <other_name>Rubraca</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Currently enrolled in a Clovis-sponsored study of rucaparib that is being closed&#xD;
&#xD;
          -  Either: (a) Is currently tolerating a rucaparib treatment regimen in the parent study&#xD;
             with evidence of clinical benefit, as assessed by the investigator, or (b) Has&#xD;
             discontinued treatment and is being followed for collection of LTFU data in the parent&#xD;
             study&#xD;
&#xD;
          -  Demonstrated compliance with the parent study requirements, as assessed by the&#xD;
             investigator, and patient is able and willing to comply with the necessary study&#xD;
             visits and assessments as part of the rollover study&#xD;
&#xD;
          -  Provided written informed consent prior to enrolling in this rollover study&#xD;
&#xD;
        Exclusion Criteria (applicable only to patients considered for continuation of rucaparib&#xD;
        treatment):&#xD;
&#xD;
          -  Patient has been permanently discontinued from study treatment in the parent study for&#xD;
             any reason&#xD;
&#xD;
          -  Pregnant or breastfeeding female patients&#xD;
&#xD;
          -  Presence of any other condition that may, in the opinion of the investigator, make the&#xD;
             patient inappropriate for continuation of rucaparib treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Haroldo Juaçaba Instituto do Câncer do Ceará</name>
      <address>
        <city>Fortaleza</city>
        <state>Ceara</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Oncologia do Paraná (IOP)</name>
      <address>
        <city>Curitiba</city>
        <state>Parana</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Câncer Hospital do Câncer II</name>
      <address>
        <city>Santo Cristo</city>
        <state>Rio De Janeiro</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CEPON - Centro de pesquisas Oncologicas</name>
      <address>
        <city>Florianópolis</city>
        <state>Santa Catarina</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Câncer de Barretos</name>
      <address>
        <city>Barretos</city>
        <state>Sao Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Perola Byington - Centro de Referencia da Saude da Mulher</name>
      <address>
        <city>São Paulo</city>
        <state>Sao Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Brasileiro de Controle do Cancer (IBCC)</name>
      <address>
        <city>São Paulo</city>
        <state>Sao Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Insitut De Recherche De L'Hospital D'Ottawa</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital - Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de L'Universite de Montreal (CHUM)</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CIUSSS de l'Estrie - CHUS</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice v Praze</name>
      <address>
        <city>Praha 2</city>
        <state>Praha</state>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultní nemocnice v Motole</name>
      <address>
        <city>Praha 5</city>
        <state>Praha</state>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultní Nemocnice Ostrava</name>
      <address>
        <city>Ostrava</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Országos Onkológiai Intézet</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carmel Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center</name>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center, Oncology Dept.</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto per la Ricerca e la Cura del Cancro Istituto di Candiolo</name>
      <address>
        <city>Candiolo</city>
        <state>Torino</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale per lo studio e la cura dei tumori &quot;Fondazione Pascale&quot; Oncologia Medica</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario Agostino Gemelli</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Białostockie Centrum Onkologii im. Marii Skłodowskiej-Curie</name>
      <address>
        <city>Białystok</city>
        <state>Podlaskie</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Specjalistyczny w Olsztynie</name>
      <address>
        <city>Olsztyn</city>
        <state>Warminsko-Mazurskie</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Republic Clinical Oncology Dispensary of the Ministry of Healthcare of Republic of Bashkortostan</name>
      <address>
        <city>Ufa</city>
        <state>Bashkortosta</state>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution Oncologic Dispensary No. 2 - Health Department of Krasnodar Region</name>
      <address>
        <city>Sochi</city>
        <state>Krasnodar</state>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Republican oncological dispensary of Republic of Mordovia</name>
      <address>
        <city>Saransk</city>
        <state>Mordovia</state>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkhangelsk Clinical Oncological Dispensary</name>
      <address>
        <city>Arkhangel'sk</city>
        <state>Primorskiy</state>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pyatigorsk Oncological Dispensary</name>
      <address>
        <city>Pyatigorsk</city>
        <state>Stavropol</state>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>N.N. Blokhin Russian Cancer Research Center</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omsk Regional Clinical Oncologic Dispensary</name>
      <address>
        <city>Omsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ryazan Regional Clinical Oncology Dispensary</name>
      <address>
        <city>Ryazan'</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almazov National Medical Research Centre</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncológico Regional de Galicia</name>
      <address>
        <city>La Coruña</city>
        <state>La Coruna</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall DHebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidad Autonoma de Madrid (UAM) - Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital Number 4 of Dnipro City Council</name>
      <address>
        <city>Dnipropetrovs'k</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute of the Ministry of Health of Ukraine</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lviv Regional Oncology Dispensary</name>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals</name>
      <address>
        <city>London</city>
        <state>England</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East and North Hertfordshire NHS Trust</name>
      <address>
        <city>Middlesex</city>
        <state>England</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Greater Glasgow and Clyde</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 14, 2020</study_first_submitted>
  <study_first_submitted_qc>December 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2020</study_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rucaparib</keyword>
  <keyword>mCRPC</keyword>
  <keyword>ovarian cancer</keyword>
  <keyword>PARP inhibitor</keyword>
  <keyword>PARPi</keyword>
  <keyword>CRPC</keyword>
  <keyword>solid tumor</keyword>
  <keyword>Clovis Oncology</keyword>
  <keyword>Antineoplastic agents</keyword>
  <keyword>Genital Neoplasms, male</keyword>
  <keyword>Prostatic Neoplasms</keyword>
  <keyword>Ovarian Neoplasms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rucaparib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

